These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18395940)

  • 21. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
    Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH; Schmand BA
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):545-51. PubMed ID: 17109476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome.
    Prasher VP; Fung N; Adams C
    Int J Geriatr Psychiatry; 2005 May; 20(5):496-7. PubMed ID: 15852458
    [No Abstract]   [Full Text] [Related]  

  • 31. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 32. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial.
    Guillem F; Chouinard S; Poulin J; Godbout R; Lalonde P; Melun P; Bentaleb LA; Stip E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):934-45. PubMed ID: 16580765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
    Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
    Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.
    Scarzella L; Costanza A; Vastola K
    Funct Neurol; 2007; 22(2):101-4. PubMed ID: 17637213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebral perfusional effects of 1-year rivastigmine treatment in Alzheimer disease: a case report.
    Ettorre E; Bersani FS; Colella F; Servello A; Minichino A; Megna V; Liberatore M; Biondi M; Marigliano V
    Riv Psichiatr; 2015; 50(4):188-91. PubMed ID: 26418600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation-flow coupling differentiates between vascular and Alzheimer type of dementia.
    Rosengarten B; Paulsen S; Molnar S; Kaschel R; Gallhofer B; Kaps M
    J Neurol Sci; 2007 Jun; 257(1-2):149-54. PubMed ID: 17321550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic effects of cholinesterase inhibition in mild Alzheimer's disease.
    Chaudhary S; Scouten A; Schwindt G; Janik R; Lee W; Sled JG; Black SE; Stefanovic B
    J Magn Reson Imaging; 2013 Jul; 38(1):26-35. PubMed ID: 23239554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivastigmine Regulates the HIF-1α/VEGF Signaling Pathway to Induce Angiogenesis and Improves the Survival of Random Flaps in Rats.
    Liu Y; Li W; Ma X; He J; Lin Y; Lin D
    Front Pharmacol; 2021; 12():818907. PubMed ID: 35126151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.